Human Complement Factor B ELISA Kit

$407.00

Catalog Number: EF7001-1

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.
Product Size:96 Well Plate

Additional information

Format

Sandwich ELISA

Entrez Gene

629

Components

Biotinylated Human Complement Factor B Antibody, Chromogen Substrate (1x), EIA Diluent Concentrate (10x), Human Complement Factor B Microplate, Human Complement Factor B Standard, Sealing Tapes, SP Conjugate (100x), Stop Solution (1x), Wash Buffer Concentrate (20x)

TIme

4 hours

Sensitivity

1.35 ng/ml

Range

2.188 – 140 ng/ml

Samples Type

CSF, Milk, Plasma, Saliva, Serum

Associated Disease

Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Species

Human

UniProt

P00751

Storage

Refer to component labels for details

Plex

1

Usage

For Research Use Only, Not To Be Used For Diagnostic Purposes

Documentation

Publications (13 results)

Please use discretion when following external links; Assaypro cannot guarantee the validity and security of all citation links provided.

The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis

Complement system abnormalities in patients with atypical hemolytic uremic syndrome and catastrophic antiphospholipid syndrome

  • http://vestnikramn.spr-journal.ru/jour/article/view/769
  • KA Demyanova, NL Kozlovskaya… - Annals of the …, 2017 - vestnikramn.spr-journal.ru
  • Background: The role of the alternative complement pathway (AP) abnormalities in the pathogenesis of aHUS is well studied. Clinical and morphological manifestations of atypical HUS …

Сравнительный анализ изменений в системе комплемента при катастрофическом антифосфолипидном синдроме и атипичном гемолитико-уремическом …

Роль изменений комплемента в развитии поражения почек у больных с микроангиопатическими синдромами

* Moiseev S et al. (2020) The alternative complement pathway in ANCA associated vasculitis: further evidence and a meta analysis. Clin Exp Immunol. 202(3):394-402.

* Andersone BJ (2020) Lymphatic Filariasis: Host and parasite factors and the pathogenesis of systemic adverse events following treatment. Washington University in St. Louis Electronic Theses and Dissertations. 2160.

* Kumar A et al. (2019) Utility of plasma exchange in early recurrent C3 glomerulopathy. Ind. J. Transplant. 13(2):122-126

* Andersen BJ et al. (2019) Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. PLoS Negl Trop Dis. 13(9):e0007697.

* Nada R et al. (2018) Renal and Pulmonary Dense Deposit Disease Presenting as Pulmonary-Renal Syndrome. Kidney Int. Rep. 3(3):755-761

* Yurova BA et al. (2017) Changes in the complement system in membranoproliferative glomerulonephritis. https://doi.org/10.17116/terarkh201789669-77.

* Demyanova KA et al. (2017) Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome. Vestn Ross Akad Med Nauk. 72(1):42-52.

* Suman S et al. (2016) Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer. J Proteomics. 148:183-93.

Loading data...